Table 4 SUCRA ranking of the incidence of SAEs
Treatment | SUCRA | PrBest | MeanRank |
|---|---|---|---|
Warfarin | 89.4 | 44.9 | 2.4 |
Ambrisentan | 81.6 | 10.3 | 3.4 |
Pamrevlumab | 80.1 | 30.5 | 3.6 |
N-acetylcysteine | 66.1 | 5.3 | 5.4 |
Simtuzumab | 54.1 | 0.1 | 7 |
Pirfenidone | 48.5 | 0 | 7.7 |
Placebo | 48 | 0 | 7.8 |
Imatinib | 44 | 1.6 | 8.3 |
Nintedanib | 42.7 | 0 | 8.5 |
Sildenafil | 38.7 | 1.2 | 9 |
Macitentan | 37.6 | 0.7 | 9.1 |
PRM151 | 34 | 4.4 | 9.6 |
Bosentan | 29 | 0 | 10.2 |
GLPG1690 | 6.1 | 1 | 13.2 |